Literature DB >> 27059188

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Kenneth C Anderson1, Melissa Alsina2, Djordje Atanackovic3, J Sybil Biermann4, Jason C Chandler5, Caitlin Costello6, Benjamin Djulbegovic2, Henry C Fung7, Cristina Gasparetto8, Kelly Godby9, Craig Hofmeister10, Leona Holmberg11, Sarah Holstein12, Carol Ann Huff13, Adetola Kassim14, Amrita Y Krishnan15, Shaji K Kumar16, Michaela Liedtke17, Matthew Lunning18, Noopur Raje19, Frederic J Reu20, Seema Singhal21, George Somlo15, Keith Stockerl-Goldstein22, Steven P Treon1, Donna Weber23, Joachim Yahalom24, Dorothy A Shead25, Rashmi Kumar25.   

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.
Copyright © 2016 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Year:  2016        PMID： 27059188      PMCID： PMC6016087          DOI： 10.6004/jnccn.2016.0046

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  26 in total

1.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

2.  Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

Authors:  Craig B Reeder; Donna E Reece; Vishal Kukreti; Joseph R Mikhael; Christine Chen; Suzanne Trudel; Kristina Laumann; Harjot Vohra; Rafael Fonseca; P Leif Bergsagel; Jose F Leis; Rodger Tiedemann; A Keith Stewart
Journal:  Br J Haematol       Date:  2014-06-30       Impact factor: 6.998

3.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

4.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Authors:  Paul G Richardson; Rachid Baz; Michael Wang; Andrzej J Jakubowiak; Jacob P Laubach; R Donald Harvey; Moshe Talpaz; Deborah Berg; Guohui Liu; Jiang Yu; Neeraj Gupta; Alessandra Di Bacco; Ai-Min Hui; Sagar Lonial
Journal:  Blood       Date:  2014-06-11       Impact factor: 22.113

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

Review 7.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Authors:  Peter Atadja
Journal:  Cancer Lett       Date:  2009-04-02       Impact factor: 8.679

8.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

9.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

10.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316
View more
  24 in total

1.  Progress and Paradigms in Multiple Myeloma.

Authors:  Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

2.  Serum free light chain quantitative assays: Dilemma of a biomarker.

Authors:  Giovanni Cigliana; Francesca Gulli; Cecilia Napodano; Krizia Pocino; Elena De Santis; Luigi Colacicco; Iole Cordone; Laura Conti; Umberto Basile
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

3.  Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.

Authors:  Adebayo Ogunniyi; Mabel Rodriguez; Sean Devlin; Nelly Adel; Heather Landau; David J Chung; Nikoletta Lendvai; Alexander Lesokhin; Guenther Koehne; Sham Mailankody; Neha Korde; Lilian Reich; Ola Landgren; Sergio Giralt; Hani Hassoun
Journal:  Leuk Lymphoma       Date:  2016-10-13

Review 4.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Authors:  Nils Winkelmann; Max Desole; Inken Hilgendorf; Thomas Ernst; Herbert G Sayer; Christa Kunert; Lars-Olof Mügge; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

6.  Should minimal residual disease negativity be the end point of myeloma therapy?

Authors:  Kenneth C Anderson
Journal:  Blood Adv       Date:  2017-03-14

7.  A 3D-Bioprinted Multiple Myeloma Model.

Authors:  Di Wu; Zongyi Wang; Jun Li; Yan Song; Manuel Everardo Mondragon Perez; Zixuan Wang; Xia Cao; Changliang Cao; Sushila Maharjan; Kenneth C Anderson; Dharminder Chauhan; Yu Shrike Zhang
Journal:  Adv Healthc Mater       Date:  2021-09-23       Impact factor: 11.092

8.  Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.

Authors:  Akira Tanimura; Risen Hirai; Miki Nakamura; Masataka Takeshita; Shotaro Hagiwara; Akiyoshi Miwa
Journal:  Int J Hematol       Date:  2018-01-31       Impact factor: 2.490

Review 9.  Next-generation CAR T cells to overcome current drawbacks.

Authors:  Stefan Lundh; Sayantan Maji; J Joseph Melenhorst
Journal:  Int J Hematol       Date:  2020-06-27       Impact factor: 2.490

10.  Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers.

Authors:  Mengtian Sun; Jingliang Cheng; Cuiping Ren; Yong Zhang; Yinhua Li; Ying Li; Suping Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.